Gilder Gagnon Howe & Co. LLC Lowers Position in Novelion Therapeutics Inc. (NASDAQ:NVLN)

Gilder Gagnon Howe & Co. LLC decreased its stake in shares of Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSE:QLT) by 93.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,833 shares of the biotechnology company’s stock after selling 309,766 shares during the period. Gilder Gagnon Howe & Co. LLC owned 0.12% of Novelion Therapeutics worth $202,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of NVLN. Stonepine Capital Management LLC raised its position in shares of Novelion Therapeutics by 2.4% in the first quarter. Stonepine Capital Management LLC now owns 1,560,487 shares of the biotechnology company’s stock valued at $16,760,000 after buying an additional 36,453 shares during the last quarter. Highbridge Capital Management LLC raised its position in shares of Novelion Therapeutics by 190.8% in the first quarter. Highbridge Capital Management LLC now owns 625,268 shares of the biotechnology company’s stock valued at $6,716,000 after buying an additional 410,268 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Novelion Therapeutics during the fourth quarter valued at about $2,803,000. Oxford Asset Management acquired a new position in shares of Novelion Therapeutics during the first quarter valued at about $1,238,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Novelion Therapeutics by 1.7% in the first quarter. Goldman Sachs Group Inc. now owns 112,902 shares of the biotechnology company’s stock valued at $1,213,000 after buying an additional 1,889 shares during the last quarter. 70.79% of the stock is currently owned by institutional investors.

Novelion Therapeutics Inc. (NASDAQ:NVLN) opened at 7.66 on Friday. The company’s 50-day moving average is $9.17 and its 200 day moving average is $9.84. Novelion Therapeutics Inc. has a one year low of $1.37 and a one year high of $12.12. The stock’s market capitalization is $142.48 million.

Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.04. The firm had revenue of $40.90 million for the quarter, compared to analyst estimates of $36.86 million. Equities analysts expect that Novelion Therapeutics Inc. will post ($1.66) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Gilder Gagnon Howe & Co. LLC Lowers Position in Novelion Therapeutics Inc. (NASDAQ:NVLN)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2017/08/12/gilder-gagnon-howe-co-llc-lowers-position-in-novelion-therapeutics-inc-nasdaqnvln.html.

Several equities analysts recently issued reports on NVLN shares. Zacks Investment Research raised shares of Novelion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Bloom Burton reissued an “accumulate” rating on shares of Novelion Therapeutics in a report on Monday, June 19th. ValuEngine lowered shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Royal Bank Of Canada set a $9.00 price objective on shares of Novelion Therapeutics and gave the company a “hold” rating in a report on Tuesday.

About Novelion Therapeutics

Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.

Institutional Ownership by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

What are top analysts saying about Novelion Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novelion Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit